Topical Rebamipide Treatment for Superior Limbic Keratoconjunctivitis in Patients with Thyroid Eye Disease – Accepted Manuscript

Abstract: Purpose: To evaluate efficacy of topical rebamipide for superior limbic keratoconjunctivitis (SLK) in patients with thyroid eye disease (TED).Design: A retrospective, observational case series.Methods: Thirty-three eyes from 20 TED patients with SLK who received topical rebamipide [Mucosta® ophthalmic suspension unit dose 2%; chemical name, (2RS)-2-(4-chlorobenzoylamino)-3-(2-oxo-1, 2-dihydroquinolin-4-yl) propanoic acid] were included. The following items were evaluated before and 4 weeks after the start of treatments: presence or absence of SLK, rose bengal staining score, AD classification (A, area; D, density) of fluorescein staining, Schirmer’s test I (without topical anesthesia), tear break-up time (TBUT), Hertel exophthalmometry values, and margin reflex distances-1 (Read more...)

Full Story →